Drug Patent Expirations : Potential Effects on Pharmaceutical Innovation.

Format:

Book

Government document

Author/Creator:

Library of Congress. Congressional Research Service. Resources, Science, and Industry Division.

Language:

English

Subjects (All):

Finance--Law and legislation.

Finance.

Business.

Intellectual property.

Marketing.

Physical Description:

1 online resource (1 online resource (21 p), digital, PDF file)

monochrome

Place of Publication:

[Place of publication not identified] : [publisher not identified], 2012.

System Details:

text file

Summary:

Provides overview of pharmaceutical industry and role of patents. Discusses impact of P.L. 98-417, the Drug Price Competition and Patent Term Restoration Act, also known as the Hatch-Waxman Act, which created several practices intended to facilitate marketing of generic drugs while permitting brand name companies to recover a portion of their intellectual property rights lost during the pharmaceutical approval process. Covers expiration of major pharmaceutical patents, and reviews innovation issues regarding "blockbuster drug" patents and innovation pipeline, drug approvals, and productivity.

Notes:

Record is based on bibliographic data in ProQuest U.S. Congressional Research Digital Collection (last viewed Apr. 2014). Reuse except for individual research requires license from ProQuest, LLC.

CRS Report.

Other Format:

Microfiche version: Library of Congress. Congressional Research Service. Resources, Science, and Industry Division. Drug Patent Expirations

Access Restriction:

Restricted for use by site license.